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Kuehl, Stanley M. Stevens Jr., and Brant R. Burkhardt*
Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, 4202 
East Fowler Avenue, Tampa, FL 33620
Abstract
PANcreatic-DERived factor (PANDER) is a member of a superfamily of FAM3 proteins 
modulating glycemic levels by metabolic regulation of the liver and pancreas. The precise 
PANDER-induced hepatic signaling mechanism is still being elucidated and has been very 
complex due to the pleiotropic nature of this novel hormone. Our PANDER transgenic (PANTG) 
mouse displays a selective hepatic insulin resistant (SHIR) phenotype whereby insulin signaling is 
blunted yet lipogenesis is increased, a phenomena observed in type 2 diabetes. To examine the 
complex PANDER-induced mechanism of SHIR, we utilized quantitative mass spectrometry based 
proteomic analysis using Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) to 
reveal the global hepatic proteome differences within the PANTG under the metabolic states of 
fasting, fed and insulin-stimulated conditions. Proteomic analysis identified lipid metabolism as 
one of the top cellular functions differentially altered in all metabolic states. Differentially 
expressed proteins within the PANTG having a lipid metabolic role included ACC, ACLY, CD36, 
CYP7A1, FASN and SCD1. Central to the differentially expressed proteins involved in lipid 
metabolism was the predicted activation of the liver X receptor (LXR) pathway. Western analysis 
validated the increased hepatic expression of LXRα along with LXR-directed targets such as 
FASN and CYP7A1 within the PANTG liver. Furthermore, recombinant PANDER was capable of 
inducing LXR promoter activity in-vitro as determined by luciferase reporter assays. Taken 
together, PANDER strongly impacts hepatic lipid metabolism across metabolic states and may 
induce a SHIR phenotype via the LXR pathway
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1. INTRODUCTION
Over the past decade PANcreatic-DERived factor (PANDER or FAM3B) has been 
investigated with regard to secretion from the endocrine pancreas and biological impact on 
glycemic regulation both in-vitro and in-vivo (Zhu, Xu, Patel et al., 2002, Burkhardt, Cook, 
Young et al., 2008, Burkhardt, Greene, White et al., 2006, Cao, Yang, Burkhardt et al., 2005, 
Hou, Wang, Li et al., 2011, Mou, Li, Yao et al., 2013, Robert, 2005, Robert-Cooperman, 
Carnegie, Wilson et al., 2010, Wang, Cai, Pang et al., 2008, Xiang, Chen and Yang, 2012, 
Xu, Gao, Wu et al., 2005, Yang, Gao, Robert et al., 2005, Yang, Robert, Burkhardt et al., 
2005, Zhuang, Guan, Gao et al., 2011). Our recently generated pancreas specific 
overexpressing transgenic mouse model (PANTG) exhibits both fasting and fed glucose 
intolerance primarily attributed to impaired hepatic insulin signaling concordantly coupled 
with both increased gluconeogenesis and lipogenesis (Robert-Cooperman, Dougan, Moak et 
al., 2014). This result is consistent with other PANDER animal models that acutely express 
PANDER within the liver via adenoviral delivery (Li, Chi, Wang et al., 2011). The 
mechanism by which PANDER inhibits hepatic insulin signaling has been attributed to 
suppressed phosphorylation of Akt (Yang, Wang, Li et al., 2009) and AMPK (Robert-
Cooperman et al., 2014). Both of which serve as major regulators of gluconeogenesis. 
However, a major paradox to PANDER signaling has been the documented increase in 
hepatic lipogenesis despite inhibited insulin signaling (Robert-Cooperman et al., 2014, Li et 
al., 2011). This bifurcation of signaling results in a selective insulin resistant state that 
mimics what is observed in T2D animal models and humans (Biddinger, Hernandez-Ono, 
Rask-Madsen et al., 2008, Brown and Goldstein, 2008). Encompassing prior PANDER 
research, an emerging hypothesis suggests that the pathophysiological conditions of T2D 
could potentially induce increased circulating PANDER levels contributing to selective 
hepatic insulin resistance (SHIR) resulting in increased hepatic glucose output and 
lipogenesis (Wilson, Robert-Cooperman and Burkhardt, 2011, Wang, Burkhardt, Guan et al., 
2012), as precisely observed in our PANTG model. Recent evidence has now indicated that 
circulating PANDER levels are elevated and associated with metabolic syndrome 
components in a Chinese population (Cao, Yang, Lai et al., 2015). Plasma PANDER levels 
significantly correlated with fasting plasma glucose, 2 hour plasma glucose, and triglyceride 
levels. Between animal model results and recent clinical studies, an emerging theme with 
PANDER is the possible role of this novel hormone in the promotion of hepatic insulin 
resistance and lipogenesis. Despite this importance, the precise PANDER-induced signaling 
mechanism in the liver has yet to be determined.
To elucidate PANDER-induced hepatic molecular mechanisms, we utilized quantitative 
mass spectrometry-based proteomic analysis via a stable isotope labeling by amino acids in 
cell culture (SILAC) approach to characterize hepatic proteomic differences between the 
PANTG murine liver with that of wild-type mice under three metabolic states: fasting, fed, 
and insulin-stimulated. To achieve this, stable isotope-labeled liver protein lysate from mice 
that were metabolically labeled with 13C6-Lys was utilized as an internal standard for 
relative quantification of global proteome differences in the liver, a technique rarely used to 
study metabolic disorders yet previously validated from examination of insulin signaling and 
liver proteomic characterization. Differentially expressed proteins using this approach can be 
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analyzed with bioinformatics tools such as Ingenuity Pathway Analysis (IPA) in order to 
reveal altered molecular networks and their function as well as differences in canonical 
pathways that can be later validated via additional molecular approaches. This unbiased, 
global-scale approach has led to novel insight into PANDER-induced hepatic pathway 
alterations in our PANTG model, in particular, those related to increased lipogenesis.
2. MATERIALS AND METHODS
2.1. Transgenic mouse generation and genotyping
Generation and original phenotyping of the PANDER transgenic mouse was described 
previously (Robert-Cooperman et al., 2014). In brief, this murine model overexpresses 
PANDER from the endocrine pancreas resulting in increased levels of circulating PANDER 
with a phenotype of impaired glucose tolerance and hepatic insulin sensitivity.
2.2. Proteomic Experimental Design
The purpose of this study was to examine the PANDER-induced hepatic proteome in various 
metabolic states. As outlined in Fig. 1, the PANTG mouse was exposed to fasted, fed, and 
insulin stimulatory conditions prior to liver extraction and subsequent proteomic 
examination. All treatments were performed on PANTG and wild-type mice at six weeks of 
age. Fed and fasted mice were withheld from food for approximately 4 and 16 hours, 
respectively. Following the 4 hour fast, fed mice were provided with chow ad-libitum for 2 
hours. Insulin-stimulated mice were fasted for 4 hours prior to insulin injection (Humulin®, 
1 unit/kg). Insulin was diluted to 20 units/ml and injected intraperitoneally with exposure for 
15 minutes. Mice were humanely euthanized by carbon dioxide asphyxiation and cervical 
dislocation following above described metabolic conditions. Livers were extracted 
immediately following exposure to described metabolic conditions, snap frozen and stored at 
−80°C prior to proteomic analysis.
2.3. Hepatic Protein Isolation
Approximately 40 mg of tissue was excised from a lobe of mouse liver for tissue lysis. 
Tissue was submerged in cold lysis buffer (100mM Tris-HCl, 100mM DTT, 4% SDS and 1x 
HALT protease inhibitor) and homogenized using a Qiagen TissueRupter. Cell lysate was 
then heated at 95°C for five minutes followed by brief sonication. The tissue lysate was 
cleared by centrifugation at 16000× g for 5 min and the supernatant was collected and stored 
at −80°C prior to further analysis. The same procedure for protein purification was 
performed on the “heavy” labeled (13C6 L-Lysine) murine male liver (MT-LYSC6-ML-PK, 
Cambridge Isotope Laboratories, Inc.).
2.4. Sample digestion, desalt and SCX fractionation
Protein concentration was quantified using the Pierce 660 nm protein assay kit supplemented 
with the provided ionic detergent compatibility reagent (IDCR). Equal mass of labeled and 
unlabeled protein or “light” and “heavy” protein respectively, were combined and digested 
using the filter-aided sample preparation (FASP) method (Expedeon). Briefly, 30 μL of the 
protein mixture (~12.5mg/ml) was added to the spin column. The lysate buffer was 
exchanged to 8M urea using centrifugation prior to alkylation by iodoacetamide. The 
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solution was then exchanged to 50 mM ammonium bicarbonate for trypsin/Lys-C digestion 
at a ratio of 1:40 (w/w). Digestion was carried out overnight in a humidified incubator at 
37°C. Peptides were eluted off the column by addition of 0.5M NaCl followed by 
centrifugation.
Samples were desalted using solid phase enrichment C18 columns (The Nest Group, Inc.). 
Briefly, columns were activated using 100% acetonitrile followed by equilibration with 0.1% 
formic acid in water. Samples were loaded onto the columns and washed three times using 
equal volumes of 0.1% formic acid in water. Samples were eluted using 90% acetonitrile/
0.1% formic acid in water and then concentrated in a vacuum concentrator (Thermo) prior to 
resuspension with 5 mM ammonium formate and 25% acetonitrile. Peptides were 
fractionated by strong cation exchange chromatography as previously described (Bell-
Temin, Culver-Cochran, Chaput et al., 2015).
2.5. LC-MS/MS and pathway analysis
Fractions were separated on a 10 cm × 75 μm I.D. reversed phase column packed with 5 μm 
C18 material with 300 Å pore size (New Objective) using 120 minute gradients of 2–40% 
ACN in 0.1% formic acid. Inline mass spectrometric analysis was performed on a hydrid 
linear ion trap-Orbitrap mass spectrometer (Orbitrap XL (Thermo Fisher Scientific). Full 
MS survey scans were performed at a resolving power of 60000, and the top 10 most 
abundant peaks were selected for subsequent MS/MS analysis in the linear ion trap. Raw 
files were processed in MaxQuant 1.2.2.5 employing the Andromeda search algorithm and 
searched against the UniprotKB reference database for Mus musculus, concatenated with 
reversed protein sequences. A second database of known contaminants provided with the 
MaxQuant suite was also employed. All fractions for each biological sample were combined 
for analysis. Constant modification of carbamidomethylation of cysteine and variable 
modifications of oxidized methionine and acetylated protein N-termini were used. 
Additionally, Lys-6 for the spike-in internal standard was set as a label in the group-specific 
parameter section. A false discovery rate of 1% was used for peptides and proteins. A 
minimum peptide length of 6 amino acids was used. Razor and unique peptides were used 
for identification and quantification. Protein ratio values were reconstructed using median 
peptide ratio values across all three biological replicates for each experimental group where 
the final ratio for each protein was calculated by determining the ratio-of-ratio (PANTG/
Internal Standard/(WT/Internal Standard). Final ratios were input into the Perseus 
processing suite (Perseus version 1.2.0.13). Statistical analysis was performed using the 
Significance A outlier test where statistical significance based on magnitude fold-change 
was established at P < 0.05. Ratio values and Uniprot Protein identification numbers of 
differentially expressed proteins were uploaded to Ingenuity Pathway Analysis (IPA) to 
determine canonical pathways, networks and upstream regulators in the liver affected by 
increased pancreas-secreted PANDER. We note that the outlier test based on the ratio 
distribution of the combined replicates was performed to increase coverage depth of 
differentially expressed proteins. The limitation of this approach is the increased false 
discovery rate of differentially expressed proteins as variance within groups is not 
specifically considered in the statistical filtering. Given only lysine-terminated tryptic 
peptides were used for relative quantitation, coverage of quantifiable proteins was limited 
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(more so for lower abundance proteins) and therefore the Significance A filtering approach 
was utilized in order to enhance bioinformatic analysis. Additionally, we have generated a 
modified ProteinGroups file generated by MaxQuant that lists relative expression ratios for 
each biological replicate, showing all proteins with measurable relative standard deviation 
(RSD) values. In order to achieve statistical significance based on 1.5-fold change in 
expression (relative to wild-type, which is a value close to the Significance A test cut-off for 
significance at p<0.05 for the three metabolic conditions) using the Student’s t-test (with the 
assumption that variance is the same at higher expression), approximately 30% RSD or less 
would be needed. For higher fold-change values (>2-fold), statistical significance using the 
Student’s t-test could be achieved at RSD values measured for most proteins in the modified 
ProteinGroups file. The modified protein list represents all hepatic proteins that are 
quantifiable with the methodology and instrumentation used in this study. This file as well as 
all mass spectrometric data have been deposited to the ProteomeXchange Consortium via 
the PRIDE partner repository with the dataset identifier PXD004171 and 10.6019/
PXD004171. In addition, further raw data and a detailed description of the proteomic 
analysis can be found in the Data in Brief manuscript associated with this study including 
Venn-Diagrams of unique proteins across metabolic states (Fig. 1, Data in Brief article) and 
complete listing of all differentially expressed proteins (Supplementary Tables 1–3, Data in 
Brief article) (Athanason, 2016).
2.6. Immunoblotting
Approximately 100 mg of tissue was excised from a lobe of mouse liver for tissue lysis. 
Liver samples were identical from those obtained during the SILAC analysis as detailed 
earlier. In brief, following isolation the liver was submerged in cold T-PER lysis buffer 
(Thermo) supplemented with 1X HALT protease inhibitor and lysed using a Qiagen 
TissueRupter until tissue debris was no longer visible. Cellular lysate was then heated at 
95°C for five minutes followed by brief sonication. The tissue lysate was cleared by 
centrifugation at 16000× g for 5 min and the supernatant was collected and stored at −80°C 
prior to further analysis. Protein concentration was quantified using the Pierce BCA Protein 
assay following the manufacturer’s protocol. Fifty μg was separated by SDS-PAGE (Mini-
PROTEAN TGX Pre-Cast gels, 4–20%) and electro-transferred to a PVDF membrane using 
the iBlot semi-dry transfer apparatus (Invitrogen). PVDF membranes were then probed with 
primary antibodies against FAS, (C20G5, Cell Signaling Technology), LXRα (P-20, Santa 
Cruz), and CYP7A1 (ab65596, Abcam). All primary antibodies were diluted 1:500 in 
StartBlock Blocking Buffer (Thermo). Detection was achieved utilizing horseradish-
peroxidase-conjugated goat secondary antibody (Bio-Rad) diluted 1:10,000 in StartBlock 
followed by chemiluminescence detection using Pierce ECL Western Blotting Substrate 
(Thermo). Emitted signal was detected using the Amersham™ Imager 600 (GE Healthcare 
Life Sciences). Relative protein levels were normalized to GAPDH (2118, Cell Signaling) 
and expression levels and densitometry analysis were quantified with ImageQuantTL (GE 
Healthcare Life Sciences).
2.7. Cell culture and transient transfections
BNL-CL2 (BALB/c embryonic normal liver) cells were cultured until passage five in 
standard DMEM (4.5g/L glucose, L-glutamine and sodium pyruvate) supplemented with 
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10% FBS and 1% PenStrep (Thermo) at 37 °C, 5% CO2. Approximately 2 × 105 cells per 
well were plated in a tissue culture treated 24-well dish (Becton-Dickinson). After 24 hours, 
media was replaced with DMEM without glucose, L-glutamine and sodium pyruvate 
supplemented with 1% FBS for 4 hours prior to transfection. LXRα signaling plasmids and 
control plasmids (Cignal Reporter Assay Kit, Qiagen) were transfected using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). Transfection of each plasmid was performed in triplicate in 
two independent experiments. Two hours post transfection, media was replaced with DMEM 
supplemented with 1% FBS and 1% PenStrep with the addition of PANDER (0.25 nM, 0.5 
nM and 1nM) for 18 hours. Cells were washed with PBS and lysed in 100 μl of 1X Glo 
Lysis Buffer (Promega), utilizing the Dual-Luciferase Reporter Assay System (Promega) for 
luciferase activation. Signal emission was detected with a Monolight 3010 luminometer 
(Analytical Luminescence Laboratory, San Diego, CA).
3. RESULTS
3.1 SILAC Proteomic characterization of PANTG liver reveals increased hepatic lipogenesis
To comprehensively examine the PANDER-induced hepatic proteome, we performed 
SILAC-based quantitative proteomics on our PANTG model. The PANTG is an ideal 
candidate for our investigation due to pancreatic-specific overexpression of PANDER 
resulting in robust increased circulating levels as compared to wild-type mice along with 
resultant impaired glucose tolerance, hepatic insulin resistance and increased hepatic 
triglyceride levels (Robert-Cooperman et al., 2014). Our quantitative proteomic approach 
was performed on the PANTG model in comparison to WT mice in the context of 3 
metabolic conditions of fasting, fed and insulin-stimulated to examine the impact of 
PANDER across numerous metabolic states. Following exposure to the various metabolic 
conditions, livers from PANTG and age/gender matched WT mice were collected and 
subsequently processed by tryptic digestion, desalting and SCX chromatography followed 
by mass spectrometry as detailed in Figure 1. Across all metabolic conditions, MaxQuant 
identified a total of 19,423 unique peptides (Complete data files deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier 
PXD004171 and 10.6019/PXD004171). Of those, there were 228, 239 and 189 significantly 
differently expressed and quantifiable proteins in the fasted, fed and insulin-stimulated 
conditions within the PANTG liver as compared to WT, respectively (Listed in 
Supplementary Table 1 and fully detailed in reference (Athanason, 2016). Based on 
proteomic examination by IPA of the differentially expressed proteins, the top predicted 
primary molecular and cellular functions altered in the PANTG for all metabolic states was 
lipid metabolism based on −log(p-value) score as determined using the Significance A 
outlier test (Fig. 2). Within the fasting, fed and insulin-stimulated conditions, 51, 42 and 50 
differentially expressed proteins, respectively, with lipogenic associated functions were 
identified (Listed in Supplementary Table 2 and fully detailed in reference (Athanason, 
2016). The most significant metabolic changes in the predicted activation state were found 
during insulin stimulation with numerous functions having a significant predicted activation 
as determined by z-score in IPA (z-score values >2 or <−2 indicate activation or inhibition, 
respectively). These functions included fatty acid synthesis, concentration of lipid, 
concentration of fatty acid, oxidation of lipid and conversion of lipid (Table 1). The most 
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significantly activated lipogenic that were identified included fatty acid synthesis and 
concentration of lipid with 27 proteins converging on these predicted activated networks 
(Figure 3).
Some of the most notable differentially expressed enzymes involved in lipogenesis included 
fatty acid synthase (FASN), ATP citrate lyase (ACLY), and sterol-CoA desaturase-1 (SCD) 
(Fig 3.).
3.2. Proteomic identification of PANDER-induced hepatic LXR pathway
Due to the significant change in hepatic lipogenesis as determined by our proteomic 
approach, a mechanism or canonical pathway was then evaluated to potentially identify the 
etiology supporting this phenotype. Therefore, IPA was used to identify putative canonical 
pathways in all metabolic states that could potentially regulate the observed lipogenic 
pathways. Network analysis revealed that Liver X Receptor activation was identified as the 
most significantly predicted overall affected pathway across metabolic states (Fig. 4). In 
addition, acute phase response signaling was also revealed as a significant canonical 
pathway.
3.3. Validation of PANDER-induced hepatic LXR pathway and fatty acid synthase 
expression
Liver X receptors (LXR) are transcription factors belonging to the class II nuclear receptor 
superfamily and are composed of 2 isoforms (Edwards, Kennedy and Mak, 2002, Steffensen 
and Gustafsson, 2004, Ducheix, Montagner, Theodorou et al., 2013). LXRα is highly 
expressed in the liver, intestine, and adipose tissues whereas LXRβ is ubiquitously 
expressed. Upon activation, LXRs form a heterodimer with the retinoid X receptor α, which 
binds to LXR response elements and enhances targeted gene expression in a functional-
dependent manner. LXRs appear to regulate overall glucose, cholesterol, bile acid, and 
triglyceride homeostasis (Baranowski, 2008). One of the most critical gene targets governed 
by LXR involved in lipogenesis is FASN, which was shown by our proteomic analysis to be 
significantly increased in PANTG livers in all metabolic states (Joseph, Laffitte, Patel et al., 
2002, Talukdar and Hillgartner, 2006) (Supplementary Table 2). Several LXR targets 
including FASN and SCD1 not only pass the Significance A outlier test based on the ratio 
distribution of the combined biological replicates but also demonstrate statistical 
significance using the t-test (p<0.05) in the insulin-stimulated group. Other targets such as 
CYP7A1 and CD36 are lower abundance proteins with limited peptide coverage, which 
affect quantitation accuracy. Therefore, these proteins require further validation by a targeted 
approach such as western blot analysis. We then sought to precisely examine expression of 
LXR and dominant targets of LXR such as FASN and CYP7A1 in the PANTG liver. Livers 
obtained during the proteomic investigation of PANTG were also examined for levels of 
LXRα expression. In brief, PANTG and WT livers obtained and snap-frozen as previously 
detailed for the proteomic analysis were probed for LXRα, FASN and CYP7A1 expression 
by western analysis. Samples from the insulin-stimulated conditions were examined since 
this metabolic condition demonstrated the most significant differentially expressed lipid 
metabolism network (Fig. 2). During insulin-stimulated conditions, LXRα was significantly 
increased (Image J, P<0.05) as compared to WT liver expression (Fig. 5). Levels of LXRβ 
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were similar between PANTG and WT (data not shown). In addition, hepatic expression of 
FASN and CYP7A1 were increased during insulin-stimulated conditions (Image J, P<0.05). 
In summary, LXRα and critical LXRα targets such as FASN and CYP7A1 were increased 
in PANTG model and indicates this pathway may potentially be activated during conditions 
of high circulating PANDER.
3.4. PANDER stimulates LXR transcriptional activity in-vitro
The above studies examined the abundance of LXR and targets of LXR in the PANTG liver. 
However, we will also wanted to determine if PANDER may govern or induce LXR 
transcriptional activity. To examine this, reporter gene analysis was performed using a 
commercially available LXR response element (LXRE) mediated luciferase assay (Qiagen, 
Cignal LXR Reporter Kit). This LXRα reporter assay measures the transcriptional activity 
of liver X receptor (LXR) and this was determined in the context of exogenous PANDER 
application. A liver derived cell line, BNL-CL2, was exposed to increasing concentrations of 
purified secreted PANDER (AstraZeneca) and LXR-directed transcriptional activity was 
measured. PANDER can significantly increase LXRE directed luciferase expression at a 
range of concentrations from 0.25 to 1 nM in a dose-dependent manner (Figure 6). 
Therefore, as matched with increased LXR expression in the liver of the PANTG, PANDER 
is also capable of directly stimulating LXR-directed transcriptional activity in-vitro.
4. DISCUSSION
This proteomic examination of the PANTG provided important mechanistic insight 
pertaining to the putative mechanism impacting lipid metabolism in the liver of mice with 
increased circulating PANDER sourced from the endocrine pancreas. Additionally, we 
demonstrated the strong utility for the implementation of quantitative mass spectrometry 
based proteomics for the investigation of metabolic disorders or the characterization of novel 
hormones regulating intracellular signaling. Evidence to date has demonstrated that 
PANDER can promote a selective hepatic insulin resistant (SHIR) phenotype whereby 
insulin signaling is partially inhibited and therefore hepatic glucose production and 
lipogenesis is increased (Robert-Cooperman et al., 2014), phenomena observed in T2D 
animal models and clinical human observations (Brown and Goldstein, 2008). Earlier studies 
demonstrated that PANDER overexpression induces fasting hyperglycemia by upregulating 
gluconeogenic gene pathways and subsequently increasing hepatic glucose output in mice 
(Robert-Cooperman et al., 2014, Li et al., 2011, Wilson, Schupp, Burkhardt et al., 2010). 
These effects were attributed to the presence of increased transcript levels of PEPCK and 
Glucose 6-phosphatase (G6Pase) due to inhibited phosphorylation of critical insulin 
signaling molecules such as Akt and AMPK. However, these similar studies revealed 
increased hepatic lipogenesis despite suppressed insulin signaling. Therefore, due to the 
complex nature of this metabolic process, we employed a comprehensive proteomic 
approach to identify putative novel mechanisms of this process. Our MS based methods 
demonstrated a proteomic profile similar to the observed lipogenic phenotype and supports 
the utility of using this tool to unravel complex signaling mechanisms.
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With the creation of our pancreas-specific overexpressing mouse model, we have recently 
reported that the PANTG mice display fasting hyperglycemia attributed to impaired hepatic 
insulin sensitivity when circulating PANDER is overexpressed. A similar proteomic 
approach in the PANTG revealed upregulation of PEPCK and indicated a mechanism of 
PANDER-induced gluconeogenesis (Robert-Cooperman et al., 2014). This approach was 
limited though since our previous SILAC analysis employed ethanol treated AML-12 cells 
(murine hepatic cell line) to serve as the control “spike-in” internal standard for the liver and 
utilized for protein comparison. In addition, the prior proteomic examination was performed 
during a random re-fed uncontrolled metabolic state. This experimental design was certainly 
not ideal for making important comparisons during metabolic states and examining changes 
in the hepatic proteome. Therefore, our current approach employed controlled metabolic 
states (fasting, controlled fed, and insulin-stimulated) with a SILAC-labeled C57BL/6J 
murine liver (not AML-12 cell line) and evaluated in the established PANTG model. In our 
current study, we utilized a metabolically labeled “SILAC” mouse liver to provide a superior 
internal standard enhancing the capability to capture differences in the PANTG liver 
proteome as compared to the WT control.
Our proteomic data strongly complements the described published studies on PANDER’s 
role in the mouse liver with regard to inducing increased hepatic lipogenesis which has long 
been attributed to hyperinsulinemia (Assimacopoulos-Jeannet, Brichard, Rencurel et al., 
1995), a hallmark of T2D and non-alcoholic fatty liver disease (Wanless and Lentz, 1990, 
Group, 1979). However, pertaining to lipid metabolism in the PANTG liver, little is known 
of the biochemistry generating the increase of lipid production, especially fatty acid 
synthesis and lipogenesis. In our study we have provided data indicating that PANDER 
overexpression acts to increase gene expression modulated by a similar nuclear binding 
protein: the liver X receptor (LXR). Insulin mediated activation of lipogenic pathways has 
been described extensively. LXR has been shown to drive overexpression of lipogenic genes 
in hyperinsulinemia conditions (Yoshikawa, Shimano, Amemiya-Kudo et al., 2001, Chen, 
Liang, Ou et al., 2004). Since the most significant effects of PANDER were observed during 
insulin-stimulatory conditions, our data suggests that PANDER acts in concert with insulin 
to potentially promote hepatic lipid production and fatty acid synthesis. Given the fact that 
PANDER does appear to be located within pancreatic β-cell insulin granules (Xu et al., 
2005, Cao, Gao, Robert et al., 2003), this co-packaging may indicate complementary 
functionality in terms of distal biological effects on target tissues such as the liver. Increased 
hepatic lipid metabolism was also observed by proteomic analysis during fasting and fed 
conditions but not to the same level of statistical significance as insulin-stimulated. There are 
several potential putative mechanisms describing this effect. As mentioned previously, 
increased lipogenic gene regulation by PPARγ regulation has been described by blunted 
FOXO1 signaling (Li et al., 2011). Interestingly, our network analysis also indicated that 
PPARγ was a significantly predicted upstream regulator of the observed lipogenic effect in 
our PANTG model (data not shown). Alternatively, recent studies have indicated that 
Carbohydrate-Responsive Element Binding Protein (ChREBP) binds directly to the 
PANDER promoter (Ratliff, Athanason, Chechele et al., 2015). This gene plays a key role in 
the control of lipogenesis through the regulation of lipogenic genes (Dentin, Benhamed, 
Hainault et al., 2006, Iizuka, 2013). PANDER may be acting in concert with ChREBP 
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enhancing PANDER-induced lipogenesis (Ratliff et al., 2015). Our current data suggests a 
novel putative mechanism that implicates LXR as a key modulator of genes driving a hepatic 
steatotic phenotype in the PANTG mice. In the insulin-stimulated condition we saw this 
effect exaggerated where downstream targets of LXR such as FASN, ACC, SCD1, CYP7A1 
and CD36 are all upregulated. Additionally, LDL was increased in the PANTG liver 
suggesting an increase of intercellular oxysterols. Oxysterol is the main activating ligand 
required for LXR-RXR dimerization (Janowski, Willy, Devi et al., 1996). LDL influx is 
mediated by certain cell membrane transporters, CD36 being one of them (Calvo, Gómez-
Coronado, Suárez et al., 1998), leading to an increase in intracellular cholesterol content that 
can be subsequently oxidized (Noguchi, Numano, Kaneda et al., 1998). Taken together, we 
have demonstrated and validated that the LXR signaling pathway may be involved in 
PANDER-induced hepatic lipogenesis.
As detailed in prior review articles, PANDER has widespread interactions with both the liver 
and the endocrine pancreas (Wilson et al., 2011, Wang et al., 2012, Yang and Guan, 2013). 
Pancreatic islets obtained from the PANDER knockout mouse (PANDER KO) displayed an 
impaired glucose stimulated insulin secretion (GSIS) (Robert-Cooperman et al., 2010). The 
mechanism for this decreased biological function has yet to be determined precisely, 
although the observed inhibited intracellular Ca2+ response is believed to have a role in the 
impaired GSIS of the PANKO model. Importantly, LXR activation has been demonstrated to 
stimulate insulin secretion upon T0901317 (agonist of LXR) activation and promoting 
expression of FASN and ACC (also increased in our PANTG) in pancreatic islets (Efanov, 
Sewing, Bokvist et al., 2004, Efanov, Sewing, Bokvist et al., 2004). Concordantly, pancreatic 
islets from LXR knockout mice have disrupted GSIS with increased lipid deposition (Gerin, 
Dolinsky, Shackman et al., 2005). Although not experimentally confirmed in the PANKO 
model, the absence of PANDER may have inhibited pancreatic LXR expression resulting in 
the observed impaired GSIS. Another highly relevant finding is that chronic LXR activation 
particularly under high glucose conditions promotes pancreatic β-cells apoptosis (Choe, 
Choi, Kim et al., 2007). An identical biological effect that was initially widely reported for 
PANDER (Cao et al., 2003). Some of the earliest investigations demonstrated that PANDER 
could induced apoptosis of pancreatic β-cells and cell lines in a time and dependent manner 
(Cao et al., 2005, Cao et al., 2003). Taken together, PANDER induced LXR activation may 
provide a central rationale for the observed pleiotropic actions of this novel hormone in both 
the liver and pancreas.
During preparation of this manuscript, the first report examining circulating PANDER is 
currently in-press and measured these levels in an Asian population (n=212, aged 40–65) 
with varying degrees of glucose intolerance and T2D (Cao, Yang, Lai et al., 2015). Cao et al. 
revealed systemic PANDER levels are significantly correlated with increased fasting blood 
glucose (FBG), triglycerides, and high-density lipoprotein cholesterol. Furthermore, logistic 
regression analysis showed circulating PANDER was associated with increased risk of IGT 
or T2D following cofounder adjustment. In general, they found that elevated plasma 
PANDER was significantly associated with numerous metabolic syndrome components, 
which is certainly consistent with our proteomic investigation and other animal model 
studies revealing increased lipogenesis or hepatic steatosis during conditions of increased 
PANDER expression. Further studies are needed and the almost near absence of human 
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clinical and physiological in-vivo data presents a major limitation in the understanding of 
PANDER and etiological role within T2D. However, our proteomic investigation certainly 
supports the findings of this initial clinical study in that increased PANDER levels are 
associated with both increased hepatic lipogenesis and it’s potential consequences in humans 
such as promoting or initiating T2D or Metabolic Syndrome. Given that LXR is an 
important gene in the regulation and homeostasis of cholesterol (Repa and Mangelsdorf, 
2000), PANDER-induced effects on cholesterol may also be mediated by the LXR pathway. 
LXR also regulates the transcription of CYP7A1, the rate limiting step of converting 
cholesterol to bile acid as to effectively rid the cell of cholesterol (Chiang, Kimmel and 
Stroup, 2001). LXR activation also promotes the generation of other lipogenic genes 
increasing lipid accumulation and fatty acid synthesis. Accompanying this is the evidence of 
increased triglycerides seen phenotypically in the PANTG mouse in previous studies 
(Robert-Cooperman et al., 2014, Li et al., 2011). Additional studies are needed to precisely 
address both the molecular mechanism of PANDER-induced lipogenesis and the potential 
detrimental consequences when circulating levels are increased in humans in terms of the 
role in both initiation and onset of T2D or hepatic steatosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Hepatic SILAC proteomics was performed on PANDER transgenic
• 3304 total unique hepatic proteins were identified
• Cellular function altered in PANTG for all metabolic states was lipid 
metabolism
• Liver-X receptor activation predicted by proteomics and validated in-vivo and 
in-vitro
• Liver-X receptor activation may regulate the pleiotropic actions of PANDER
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Figure 1. SILAC proteomic experimental approach for investigation of PANTG
A & B. Age and gender matched PANTG and WT mice at six weeks of age (N=3 per 
condition) were exposed to three metabolic states prior to liver extraction: fed, fasted and 
insulin-stimulated. Livers were immediately extracted following exposure to described 
metabolic conditions, snap-frozen and stored at −80°C. C. & D. 40 mg of liver tissue were 
lysed in cold lysis buffer (100mM Tris-HCl, 100mM DTT, 4% SDS and 1x HALT protease 
inhibitor) prior to heating at 95°C for five minutes followed by brief sonication. Identical 
process was performed on lives obtained from metabolically labeled “SILAC” mice 
(Cambridge Isotopes). The “heavy” protein lysate was combined with each experimental 
mouse liver protein lysate prior to tryptic digestion utilizing the FASP (Expedeon) method. 
Samples were desalted using solid phase enrichment C18 columns (The Nest Group, Inc.). 
Prior to LC-MS/MS, sample complexity was reduced by strong cation exchange 
chromatography. E. & F. Each biological sample was analyzed by tandem mass 
spectrometry. Normalized ratios from MaxQuant for each biological sample were inputted 
into the Perseus processing suite to determine statistical significance of quantitation values 
using a student’s two-tailed t test (p < 0.05) yielding 231 proteins in the fed condition, 246 
proteins in the fasted condition and 191 proteins in the insulin-stimulated condition. 
Geometric means and Uniprot Protein Identification numbers were uploaded to Ingenuity 
Pathway Analysis (IPA) for canonical pathway and network analysis altered in the liver of 
mice with increased circulating PANDER.
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Figure 2. IPA determination of altered molecular and cellular functions with the PANTG liver
Molecular and cellular function analysis was determined based on the identified 
differentially expressed proteins of the PANTG and WT liver expression. Only functions that 
were identified in all metabolic states of insulin-stimulated (Top Bar, White Fill), fed 
(Middle Bar, Gray Fill) and fasting (Bottom Bar, Black Fill) conditions with a score cutoff 
of −log(p-value) greater than two are shown as determined by Fisher’s Exact test.
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Figure 3. Network analysis of significantly differentially expressed lipogenic associated proteins 
during insulin stimulatory conditions in PANTG liver
Proteins with a positive association with increased lipogenic states of both fatty acid 
metabolism and concentration of lipid are shown. Orange dotted lines indicate strong direct 
association between shown proteins and the predicted activation of fatty acid metabolism 
and concentration of lipid. The outer nodes represent differentially expressed proteins where 
red and green represent up- and downregulation, respectively. Protein names are as follows, 
CYP2C8- cytochrome P450, family 2, subfamily C, polypeptide 8, ACLY- ATP citrate lyase, 
ACOT13- acyl-CoA thioesterase 13, C3- complement component 3, ENTPD5- 
ectonucleoside triphosphate diphosphohydrolase 5, EPHX1- epoxide hydrolase 1, FABP1 
fatty acid binding protein 1, FABP2- fatty acid binding protein 2, FASN- fatty acid synthase, 
HMOX1- heme oxygenase 1, LSS- lanosterol synthase, SCD- stearoyl-CoA desaturase, 
SEC16B- SEC16 homolog B, endoplasmic reticulum export factor, SLC9A3R1- solute 
carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 1, 
SORBS1- sorbin and SH3 domain containing 1, STEAP4- STEAP family member 4, and 
THRSP- thyroid hormone responsive.
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Figure 4. Canonical pathway analysis of significantly differentially expressed proteins during all 
metabolic conditions in PANTG liver
Canonical pathways with a score cutoff of −log(p-value) greater than 5 as determined by 
Fisher’s Exact test and z-score greater than 2 are shown in metabolic states of insulin-
stimulated (Top Bar, White Fill), fed (Middle Bar, Gray Fill) and fasting (Bottom Bar, Black 
Fill).
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Figure 5. Western blotting and validation of LXRα and LXR targets (FASN and CYP7A1) in 
insulin-stimulated PANTG mice
(A) Liver lysate (40 μg) from age and gender matched PANTG mice during overnight 
fasting and insulin-stimulated conditions (n=3). Immunoblotting was performed to measure 
expression of LXRα, FASN, CYP7A1 and loading control of GAPDH. Lanes: 1–3 and 4–6 
are WT and TG liver lysate, respectively. Densitometric analysis on (B) LXRα expression; 
(C) FASN and (D) CYP7A1. * P < 0.05 (ImageJ) for both conditions.
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Figure 6. PANDER increased LXRE transcriptional activity in BNL-CL2 cells
Reporter gene analysis was performed on BNL-CL2 liver-derived cells transfected with 
LXRE-luciferase plasmids exposed to increasing concentrations of purified secreted 
PANDER (AstraZeneca) followed by measurement of luciferase activity. Treatments 
performed in triplicate in duplicate biological experiments. *** denotes P < 0.001 as 
determined by Students t-test from 0 nM PANDER condition.
Athanason et al. Page 21
Mol Cell Endocrinol. Author manuscript; available in PMC 2018 January 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Athanason et al. Page 22
Table 1
List of metabolic functions with significantly predicted increased activation state based on activation z-score 
identified during insulin conditions within PANTG liver as compared to WT.
Metabolic Functions Predicted Activation State Activation z-score Total Proteins
fatty acid synthesis Increased 2.9 27
concentration of lipid Increased 2.57 26
oxidation of lipid Increased 2.58 14
concentration of fatty acid Increased 2.42 13
conversion of lipid Increased 2.77 9
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